Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AnaptysBio, Inc. ANAB

Healthcare  —  Biotechnology
51.00 (0.70) (1.35%) as of 25 Sep
Market cap
$1.6B
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

AnaptysBio, Inc. (ANAB) Business Profile

Updated before January 2025

Company Overview

AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company headquartered in San Diego, California. Founded in 2005, the company specializes in the discovery and development of therapeutic antibodies for the treatment of inflammatory diseases and cancer. AnaptysBio leverages its proprietary somatic hypermutation (SHM) antibody platform to develop innovative therapies that address unmet medical needs. The company was co-founded by Dr. Andrew Chan and Dr. William Boyle, both of whom have extensive experience in immunology and antibody research. The current CEO of AnaptysBio is Daniel Faga, who brings a wealth of experience in biotechnology leadership and strategic development. The company’s leadership team also includes experts in clinical development, regulatory affairs, and business operations, ensuring a well-rounded approach to achieving its mission.

Core Business Segments

AnaptysBio focuses on two primary therapeutic areas: inflammatory diseases and oncology. The company’s pipeline includes several monoclonal antibody candidates designed to modulate immune system activity.

Inflammatory Diseases

AnaptysBio’s lead product candidates in this segment include:

  • Imsidolimab (ANB019): A monoclonal antibody targeting the interleukin-36 receptor (IL-36R), currently in clinical trials for the treatment of generalized pustular psoriasis (GPP) and other inflammatory conditions.
  • Rosnilimab (ANB030): A PD-1 agonist antibody designed to treat autoimmune diseases by modulating T-cell activity.

Oncology

In the oncology space, AnaptysBio is developing innovative therapies aimed at enhancing the immune system’s ability to fight cancer. Key candidates include:

  • ANB032: A monoclonal antibody targeting BTLA (B and T lymphocyte attenuator), which is being evaluated for its potential to enhance anti-tumor immunity.

Business Model

AnaptysBio operates as a research-driven biotechnology company, focusing on the discovery and early-stage development of therapeutic antibodies. The company generates revenue primarily through collaborations and licensing agreements with larger pharmaceutical companies. By leveraging its proprietary SHM antibody platform, AnaptysBio partners with industry leaders to co-develop and commercialize its therapeutic candidates. This approach allows the company to focus on its core strengths in antibody discovery while benefiting from the resources and expertise of its partners.

Strategic Direction

AnaptysBio is committed to advancing its pipeline of therapeutic antibodies to address unmet medical needs in inflammatory diseases and oncology. The company’s strategic priorities include:

  • Pipeline Expansion: Continuing to develop its existing product candidates while exploring new targets for antibody-based therapies.
  • Partnerships: Strengthening collaborations with pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability: Incorporating sustainable practices into its operations, including reducing its environmental footprint and promoting diversity and inclusion within its workforce.

Competitive Landscape

AnaptysBio operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its expertise in antibody-based therapies, particularly in the areas of immunology and oncology.
  • Amgen: A leader in biotechnology with a strong focus on innovative therapies for inflammatory diseases and cancer.
  • Bristol-Myers Squibb: A global biopharmaceutical company with a robust pipeline of immuno-oncology therapies.
  • Smaller Biotech Firms: Companies such as Allakos and Arena Pharmaceuticals, which are also developing therapies for inflammatory diseases.

Risk Factors

AnaptysBio faces several risks that could impact its business operations and financial performance:

  • Clinical Trial Risks: The success of the company’s product candidates depends on the outcomes of clinical trials, which are inherently uncertain and time-consuming.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and lengthy process, with no guarantee of success.
  • Market Dependence: The company’s revenue is heavily reliant on its ability to successfully commercialize its product candidates.
  • Supply Chain Disruptions: Delays or disruptions in the supply chain could impact the production and distribution of its therapies.
  • Competition: Intense competition in the biotechnology sector could limit the company’s market share and profitability.

Recent Developments

AnaptysBio has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive interim results from its Phase 2 clinical trial of Imsidolimab for the treatment of GPP, demonstrating its potential as a first-in-class therapy.
  • Partnerships: AnaptysBio expanded its collaboration with a leading pharmaceutical company to co-develop and commercialize its antibody candidates.
  • Corporate Strategy: The company implemented a new strategic plan focused on accelerating the development of its pipeline and optimizing its operational efficiency.

Investment Considerations

Strengths

  • Innovative Platform: AnaptysBio’s proprietary SHM antibody platform provides a competitive edge in the discovery of therapeutic antibodies.
  • Strong Pipeline: The company has a robust pipeline of product candidates targeting high-value therapeutic areas.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance its development capabilities and reduce financial risk.

Risks

  • Early-Stage Development: As a clinical-stage company, AnaptysBio has no approved products and relies on external funding to support its operations.
  • Regulatory and Clinical Risks: The success of its pipeline depends on the outcomes of clinical trials and regulatory approvals.
  • Market Competition: Intense competition from larger pharmaceutical companies and other biotech firms could impact its market potential.

Conclusion

AnaptysBio, Inc. is a promising biotechnology company with a strong focus on developing innovative antibody-based therapies for inflammatory diseases and cancer. While the company faces significant risks associated with clinical development and regulatory approval, its proprietary SHM antibody platform and strategic partnerships position it well for future growth. Investors should carefully consider the company’s strengths and risks before making investment decisions. With a robust pipeline and a commitment to addressing unmet medical needs, AnaptysBio is poised to make a meaningful impact in the biotechnology sector.